Kornimate/medical-research-clean huggingface dataset:
alveolar recruitment in brain injury

Conditions: Brain Injury; Acute Lung Injury

Summary: development of acute lung injury (ali) and acute respiratory distress syndrome (ards) in patients with severe brain injury has been associated with poor outcome. the application of lung recruitment maneuvers (rm) for a short period of time to open collapsed alveoli and reverse hypoxemia in early ards has been recommended. however, little is known about the cerebral and vascular effects of rm in brain injury patients with ali/ards. the aim of this study is to assess the effects of a single standardized rm on oxygenation and on systemic and cerebral hemodynamics in severe brain injury patients with ali/ards.

patients with severe brain injury comprise a significant portion of admissions to critical care units. these patients are unable to adequately protect their airways and are usually intubated and mechanically ventilated. the goal of mechanical ventilation in patients with brain injury is to optimize blood gas exchange while minimizing intrathoracic pressure to avoid interference with cerebral venous drainage.over the last 20 years, a plethora of experimental and clinical data have shown that mechanical ventilation can cause or aggravate lung damage in patients with acute lung injury (ali) and the acute respiratory distress syndrome (ards). the aim of this pilot study was to assess the effects of a single standardized recruitment maneuver (rm) on oxygenation and on systemic and cerebral hemodynamics in severe brain injury patients with ali/ards. only patients with brain injury, as defined by a glasgow coma score \<13, admitted into the trauma and surgical intensive care unit (icu) will be studied. after obtaining informed consent, a rm will be performed by switching the ventilator from assist/control ventilation to continuous positive airway pressure (cpap) and applying a pressure of 40 cmh2o for 40 sec (11). after the rm, patients have been ventilated in pressure control ventilation and peep will be gradually reduced in decremental steps every 3 respiratory cycles starting with peep at 30 cm h2o, maintaining a maximum peak pressure of 40 cmh2o during this procedure until pre-rm peep levels are achieved. the rm will be discontinued if any of the following changes developed during the procedure: (i) ≥20% changes in baseline systemic blood pressure, (ii) icp ≥20 mmhg, or (iii) sao2 ≤90%. after the rm is performed, respiratory mechanics, arterial and sjo2 blood samples and systemic and cerebral hemodynamics will be obtained at 30 min and 8 hours.

Eligibility criteria:
inclusion criteria: * patients with brain injury who met the ali/ards criteria within 72 hours after icu admission exclusion criteria: * \<18 years of age * cardiogenic edema * hemodynamic instability * intracranial hypertension

Keywords: brain injury mechanical ventilation acute lung injury lung recruitment
conduction system vs surgical left ventricular epicardial pacing for coronary sinus lead failure

Conditions: Heart Failure With Reduced Ejection Fraction

Summary: this a single-center, retrospective, observational study of patients that undergo coronary sinus(cs) lead revision, comparing epicardial lead placement to coronary sinus pacing(csp) in those that had lead failure.

cardiac resynchronization therapy with defibrillator(crt-d) improves quality of life, functionality, and even mortality for select patients with severe heart failure with reduced ejection fraction (hfref). it traditionally consists of three leads placed endovascularly into the right atrium, right ventricle, and left ventricle (lv) \[typically placed into the cs\], known as biventricular pacing resynchronization (bvp-crt), respectively, from which electrical stimulation enables improved cardiac synchrony. nonetheless, the placement of a crt-d is not without risks. lead-related complication is high and crt-d implantation fails in up to 30% of patients due to lead placement alone. epicardial lead placement and csp have been deemed viable alternatives to crt-d. it has even been shown to be options in patients that fail conventional bvp-crt. this is primarily due to increased accuracy, decreased complications, and even durability. however, guidelines for decision between a transthoracic approach and csp is unclear, even more so after lead failure. instead, this decision is currently individualized to the patient. there is a lack of prospective and head-to-head data between the two, and this study is aimed to compare transthoracic lv epicardial lead placement and csp in patients with lead failure after bvp-crt.

Eligibility criteria:
inclusion criteria: * all patients older than 18 years of age * patients with hfref that underwent bvp-crt * experienced cs lead failure, whether initial or recurrent, subsequently replaced with transthoracic epicardial lead placement or csp * underwent medtronic, boston scientific, or abbott lead placement exclusion criteria: * patients younger than 18 years of age * transthoracic epicardial lead placement or csp performed as the initial approach or for other reasons than lead replacement * those for which crt no longer provides symptom relief or mortality benefit.
therapeutic virtual reality: helps reduce anxiety and pain during bronchial fibroscopies in lung transplant patients.

Conditions: Anxiety; Stress; Pain; Bronchial Fibroscopy; Pulmonary Transplantation

Summary: marie lannelongue hospital is a hospital specialized in lung transplantation. lung transplant patients require regular check-ups by bronchial fibroscopy. this examination is known to be anxious, stressful and sometimes painful. these patients take many medications (immunosuppressants, antibiotics....) that may interact with analgesic or anxiolytic drugs. the objective is to propose to hml lung transplant patients a virtual reality solution containing visual and auditory 3d experiences to fight against anxiety and pain during repetitive and anxiogenic examinations such as bronchial fibroscopies. translated with www.deepl.com/translator (free version)


Eligibility criteria:
inclusion criteria: * patient with a lung or cardio-pulmonary transplant * adults (age \> 18 years old) * patient who give their informed consent for the protocol * patient requiring a bronchial fibroscopy and having already had at least one - bronchial fibroscopy without virtual reality exclusion criteria: - children
imaging tau in alzheimer's disease and normal aging

Conditions: Alzheimer's Disease

Summary: this study is being done to learn about tau tangles in alzheimer's disease. a type of pet scan is used to measure the abnormal accumulation of protein called tau in the brain. these are thought to be involved in alzheimer's disease. the investigators will also perform brain mri and to tests to measure the participant's memory and thinking.

this study is being done to determine the relationship between tau tangles and cognitive impairment in elderly subjects with different clinical and biomarker profiles of alzheimer's disease (ad). subjects will undergo screen that includes neuropsychological testing and brain mri. this study uses a special type of scan called a pet scan to take pictures of the brain. during the pet scan, a special radioactive dye called 18f-thk-5351 is injected into the body. 18f-thk-5351 sticks to abnormal tangles made of the protein tau. subjects will have the option to have lumbar puncture performed to measure csf concentrations of biomarkers.

Eligibility criteria:
inclusion criteria: 1. age 50 and older. 2. meet criteria for either a) amnestic mild cognitive impairment (single or mixed domain) or mild alzheimer's disease, or b) have no cognitive impairment, based on history, exam, neuropsychological testing, and consensus diagnosis. mci and mild ad patients must have clinical dementia rating scale score of 0.5 or 1. unimpaired subjects must have clinical dementia rating scale score of 0. 3. subjects unable to provide informed consent must have a surrogate decision maker. 4. written and oral fluency in english or spanish. 5. able to participate in all scheduled evaluations and to complete all required tests and procedures. 6. in the opinion of the investigator, the subject must be considered likely to comply with the study protocol and to have a high probability of completing the study. exclusion criteria: 1. past or present history of certain brain disorders other than mci or ad. 2. certain significant medical conditions, which make study procedures of the current study unsafe. such serious medical conditions include uncontrolled epilepsy and multiple serious injuries. 3. contraindication to mri scanning. 4. conditions precluding entry into the scanners (e.g. morbid obesity, claustrophobia, etc.). 5. history of kidney disease or presence of impaired kidney function based on laboratory tests at the screening visit. 6. history of liver disease or presence of impaired liver function based on laboratory tests at the screening visit. 7. participation in the last year in a clinical trial for a disease-modifying drug for ad. 8. inability to have a catheter in subject's vein for the injection of radioligand. 9. inability to have blood drawn from subject's veins.

Keywords: inflammation aging mild cognitive impairment
german stroke registry - endovascular treatment

Conditions: Acute Ischemic Stroke

Summary: the german stroke registry (gsr) endovascular treatment is an academic, independent, prospective, multicentre, observational registry study. consecutive patients treated with endovascular stroke treatment will be enrolled in german stroke centers. patients receive regular care and data will be collected as part of clinical routine. baseline clinical and procedural information as well clinical follow-up information during in-hospital stay, and up to 90 days of stroke onset are collected. data collected include demographics, national institute of health stroke scale (nihss) on admission, pre-treatment aspects, information on timing and success of interventional treatment, procedural complications, intracranial hemorrhage, and functional outcome.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of acute ischemic stroke * eligible for intravenous thrombolysis (ivt) and ivt initiated within 4.5 hours after stroke onset * confirmed diagnosis of persistent occlusion of terminal carotid artery, middle cerebral artery (m1 or m2), or basilar artery consistent with symptoms * age \>18 years * ethic approval in process exclusion criteria: none

Keywords: acute stroke, thrombectomy, endovascular treatment
characterization of metabolic biomarkers in varying subjects

Conditions: Obesity; Type 2 Diabetes

Summary: traditional dietary, lifestyle, behavioral and pharmacologic treatment strategies have proven relatively ineffective for treating obesity, and once metabolic abnormalities such as type 2 diabetes (t2d) develop, definitive strategies to prevent major cardiovascular events remain elusive. more positively, the identification of a scientific resolution for obesity and t2d in the short-term is not outside the bounds of reality. because the complexity of metabolic regulation is likely to include already characterized biomarkers, as well as other unidentified factors, it is logical to sample subjects of various ages, gender, ethnicity, body mass distribution, dietary habits, exercise habits, medication requirements, and disease states to discover associations and pathways related to the restoration of normal metabolism.

as an observational study design, study investigators will prospectively identify potential subjects from various primary care and/or specialty care clinics in western new york. prior to the commencement of any study procedures, subjects will document informed consent and acknowledgement of hippa rights. following approval from their practitioner, subjects may be asked on multiple occasions to complete or undergo any or all of the following types of study procedures: * medical record review and follow-up * fasting blood sample (volume limitations stipulated within) * pre-meal, during meal, and post-meal blood sample (volume limits within) * short-term and/or long-term dietary intervention (md approved) * short-term and/or long-term exercise intervention (md approved) * blood glucose log * food and exercise diaries * pre- and post-medication blood sampling (neutraceutical or rx products) * 24-hour urine sampling * spot urine sampling * stool microbiologic sampling * intestinal microbiologic sampling (gastric bypass subjects only)

Eligibility criteria:
inclusion criteria: * age =\>18 * weight =\>110 pounds exclusion criteria: * age \<18 * weight \<110 pounds * pregnant * poor venous access or poor likelihood to adhere with study procedures
self assembling peptide p11-4 in patients with early occlusal carious lesions

Conditions: Dental Caries

Summary: objectives: occlusal surfaces of erupting permanent molars are highly prone to caries. self-assembling peptide (p11-4) has proven to enhance biomimetic mineralization of early carious lesions. aim of this study was to evaluate safety, clinical applicability and effect of using p11-4 (curodont™ repair) in non-invasive treatment of early occlusal lesions. methods: 70 patients with active early occlusal lesions (icdas-ii:1-3) on first or second permanent molars at eruption will be allocated in this randomized, controlled, single blinded study to test (curodont™ repair+duraphat®) or control (duraphat®) groups.

objectives: occlusal surfaces of erupting permanent molars are high prone to caries. self-assembling peptide (p11-4) has proven to enhance biomimetic mineralization of early carious lesions. aim of this study was to evaluate safety, clinical applicability and effect of using p11-4 (curodont™ repair) in non-invasive treatment of early occlusal lesions. methods: 70 patients with active early occlusal lesions (icdas-ii:1-3) on first or second permanent molars at eruption will be allocated in this randomized, controlled, single blinded study to test (curodont™ repair+duraphat®) or control (duraphat®) groups. safety and applicability will be evaluated using dentist's/patient's questionnaires about adverse events, difficulties of application and satisfaction with procedure. lesions will be assessed at baseline and recalls after 3 and 6 months regarding caries activity, clinical status (icdas-ii) and with diagnodent®. the visual analog scale (vas) of regression and of lesion size in addition to the global impression of change questionnaire will also be assessed. at every recall, fluoride varnish will be applied on lesions and patients received oral health instructions.

Eligibility criteria:
inclusion criteria: * early occlusal carious lesions (without cavity) on permanent molar "6" or "7" at eruption which does not require an invasive treatment * age ≥ 5 years * size and form of the lesions: the lesions must both be fully visible and assessable and accessible * willing and able to attend the on-study visits and to observe good oral hygiene throughout the study * written informed consent before participation in the study exclusion criteria: * evidence of tooth erosion * fluoride varnish application \< 3 months prior to study treatment * history of head and neck illnesses (e.g. head/neck cancer) * any pathology or concomitant medication affecting salivary flow or dry mouth * any metabolic disorders affecting bone turnover * concurrent participation in another clinical trial
intravenous thrombolysis registry for acute ischemic stroke in china

Conditions: Ischemic Stroke

Summary: to analyze the real situation of intravenous thrombolysis in acute ischemic stroke in china

compare the efficacy and safety of different thrombolytic drugs; analysis of patients during hospital treatment of adverse events and complications; analysis of factors that affect the effectiveness of treatment; evaluate the pharmacological benefits of different thrombolytic drugs

Eligibility criteria:
inclusion criteria: * 1) age\> 18 years old; * 2) meet the diagnostic criteria of china 2014 guidelines for the diagnosis and treatment of acute ischemic stroke; * 3) no history of first sepsis or previous cerebral infarction sequelae (mrs ≤ 1); * 4) within 3 hours of onset; * 5) have measurable neurological deficits; * 6) patients or legal guardians can understand and sign informed consent. exclusion criteria: * absolute exclusion criteria: * 1) history of head trauma or stroke within the last 3 months; * 2) suspected subarachnoid hemorrhage; * 3) history of previous intracranial hemorrhage; * 4) intracranial tumor, arteriovenous malformation or aneurysm ; * 5) recent intracranial or intraspinal surgery; * 6) arterial puncture at an incurable site within the last 7 days; * 7) elevated blood pressure: systolic blood pressure ≥180 mm hg, or diastolic blood pressure ≥100 mm hg; * 8) internal bleeding; * 9) acute bleeding tendency, including platelet count less than 100 × 109 / l or other conditions; * 10) heparin treatment within 48 h (aptt is outside the upper limit of normal range); * 11) oral anticoagulant, inr\> 1.7 or pt\> 15s; * 12) are currently using thrombin inhibitors or factor xa inhibitors, various sensitive laboratory abnormalities (such as aptt, inr, platelet count, ect; tt or appropriate factor xa activity assays) ; * 13) blood glucose \<50 mg / dl (2.7 mmol / l); * 14) ct suggestive of multiple cerebral infarction (low density range\> 1/3 of the cerebral hemispheres) ; * 15) other conditions considered unsuitable for inclusion in this clinical study; * 16) 3 months or are participating in other clinical trials; * 17) combined with severe systemic disease is expected to survive less than three months. * relative exclusion criteria: * 1) severe stroke (nihss\> 25 points); * 2) pregnancy; * 3) neurological deficits after epileptic seizures; * 4) major surgery or severe trauma within the last 14 days; * 5) urethral hemorrhage; * 6) myocardial infarction within the last 3 months;

Keywords: alteplase; urokinase; intravenous thrombolysis
cei van outreach screening study

Conditions: Glaucoma; Macular Disease; Keratoconus

Summary: the primary goal of the trial is to show that optical coherence tomography (oct) technology can be used to effectively screen for diseases of the eye including glaucoma, macular diseases and keratoconus. glaucoma is a disease that causes permanent vision loss and is usually accompanied by increased eye pressure. macular diseases affect sharp, central vision. keratoconus is a disease that affects the cornea (clear surface covering the colored part of the eye).

the identification of many eye diseases would significantly benefit from earlier detection than is available with typical eye exams. optical coherence tomography (oct) is an imaging technology that can perform non-contact cross-sectional imaging of tissue structure in real time. it is similar to ultrasound b-mode imaging, except that oct measures the intensity of reflected light rather than sound waves.

Eligibility criteria:
inclusion criteria: * participant undergoing a screening examination at the casey eye institute outreach van. * participants must be between the ages of 18 and 89 years old. exclusion criteria: * inability to give informed consent. * inability to maintain stable fixation for oct imaging

Keywords: optical coherence tomography glaucoma macula keratoconus screening
ibuprofen versus placebo for muscle soreness

Conditions: Muscle Soreness

Summary: the study will assess the sensitivity of the delayed onset muscle soreness model by comparing the safety and efficacy of oral ibuprofen to placebo over 24 hours.

this is a double-blind, randomized, placebo controlled, parallel group, pilot safety and efficacy study. healthy male or female subjects who have a history of occasional muscle soreness and are not currently exercising will be asked to volunteer for the study. all subjects will complete an informed consent process prior to study procedures. the study duration is anticipated to be approximately 4 months. each subject may be in the study for up to 45 days including screening, run-in, inpatient and outpatient dosing and assessments, follow-up visit and follow-up telephone contact.

Eligibility criteria:
subjects must meet the following criteria to be included in the study: 1. male or female subjects aged 18-55 years; 2. in good general health; 3. non-pregnant, non-lactating female subjects must be: 1. physically incapable of childbearing potential (postmenopausal for more than 1 year or surgically sterile) or 2. practicing an acceptable method of contraception (hormonal, barrier with spermicide, intrauterine device, vasectomized or same sex partner, or abstinence). subjects using hormonal birth control must have been on a stable dose of treatment for at least 30 days and received at least 1 cycle of treatment prior to randomization. 4. history of experiencing muscle pain/soreness after moderately strenuous exercise; subjects are excluded from the study if any of the following criteria apply: 1. currently participating in an exercise regimen. 2. have an allergy or intolerance to any nsaid, aspirin, acetaminophen or lactose; 3. history of rhabdomyolysis; 4. have participated in an investigational study within the past 30 days of screening; 5. are an employee or relative of an employee of the study site (directly involved with the study).
differences and wearing safety and comfort of new defocus incorporated multiple segments spectacle lenses

Conditions: Myopia, Progressive

Summary: to evaluate the differences in controlling the progression of myopia in adolescents and the safety and comfort of wearing different types of defocus incorporated multiple segments spectacle lenses, to explore the feasibility of effective defocus micro lens design, and apply personalized defocus frame lenses for myopia prevention and control.


Eligibility criteria:
inclusion criteria: 1. age: 6-14 years old; 2. after using 1% cyclohexanone hydrochloride eye drops (saifeijie) for ciliary muscle paralysis, binocular spherical power were within 0.00d\~-4.00d, binocular cylinder power ≤ 1.50d, the anisometropia is less than 1.50d, and the best corrected visual acuity was above 5.0; 3. within 30 days, the myopia prevention and control methods such as multifocal glasses, orthokeratology, defocusing flexible glasses, progressive glasses, atropine eye drops, red light and acupuncture and moxibustion treatment were not used; 4. the subject has a willingness to receive treatment and an informed consent form is signed by their legal guardian. exclusion criteria: 1. diagnosed constant strabismus; 2. diagnosed pathological myopia; 3. other congenital eye diseases; 4. researchers believe that the patients have other reasons that are not suitable for inclusion in the project.
screening cedm in intermediate and high-risk patient populations

Conditions: Breast Cancer

Summary: this research study is being done to determine if contrast enhanced digital mammography (cedm) can improve breast cancer detection and can be used as an additional screening method to the standard mammographic screening.


Eligibility criteria:
inclusion criteria: * women aged 35 and had a negative routine mammogram within 6 months. * qualifies as intermediate or high-risk (\>15% lifetime risk of breast cancer as defined by ibis version 8). exclusion criteria: * known breast cancer * previously had negative mbi or mri within 12 months of study * pregnant or lactating * contraindication to intravenous iodinated contrast * unable to understand or sign informed consent * self-reported signs or symptoms of breast cancer